Search
for
Sort by
Research 30 of 1000+
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- 2,3,7,8‐Tetrachlorodibenzo‐<i>p</i>‐dioxin causes an increase in protein kinases growth hepatic associated with epidermal factor receptor in the plasma membrane
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- 078 The transmembrane protein LRIG1 regulates receptor tyrosine kinases in skin development and homeostasis
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Hair Growth After Gefitinib Treatment
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Periocular Manifestations of Afatinib Therapy
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
- A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
- 3D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response
- Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development
- Expression Profiles of Tyrosine Kinases in Cultured Follicular Papilla Cells Versus Dermal Fibroblasts
- Regulation and Role of GLI1 in Cutaneous Squamous Cell Carcinoma Pathogenesis
- Identification of key genes and signaling pathways related to Hetian sheep wool density by RNA-seq technology
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor